Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 45

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 45
---
 Plus (less), average year over year change in fair value of outstanding and unvested equity awards granted in prior years                            |     |   -712,629 |
| Plus (less), average change in fair value from prior fiscal year end to vesting date of equity awards granted in prior years that vested in the year |     | -1,253,923 |
| Less, prior year-end fair value for any equity awards forfeited in the year                                                                          |     |          — |
| Less, change in accumulated benefits under defined benefit and actuarial pension plans reported in Summary Compensation Table                        |     |    -22,343 |

31

TABLE OF CONTENTS

| Average Compensation Actually Paid to Non-PEO NEOs                                                                                                                                         |     |       2024 |
| Plus, aggregate defined benefit and actuarial pension plan service cost and prior service cost                                                                                             |     |     20,447 |
| Plus, dividends or other earnings paid on awards in the covered fiscal year prior to vesting if not otherwise included in the Summary Compensation Table Total for the covered fiscal year |     |          — |
| Average Compensation Actually Paid to Non-PEO NEOs                                                                                                                                         |     | $(800,701) |

| (5) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s stock price at the end and the beginning of the measurement period by the Company’s stock price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2021. No dividends were paid during the periods presented. |

| (6) | The peer group used for this purpose is the Nasdaq Biotechnology Index. |

| (7) | The dollar amounts reported represent the amount of net loss attributable to controlling interest shareholders, reflected in the Company’s audited financial statements for the applicable year. |

| (8) | The Companydoes not use any financial performance measuresto link executive compensation actually paid to Company performance. Consequently, no “Company Selected Measure” is included in the table above. |

Analysis of the Information Presented in the Pay versus Performance Table Our executive compensation program reflects a variable pay-for-performance philosophy. While we utilize several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, we generally seek to incentivize long-term performance, and therefore do not specifically align